menu
    • menu
    [{"orgOrder":0,"company":"Baring Private Equity Asia","sponsor":"Hutchmed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Savolitinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Baring Private Equity Asia","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Baring Private Equity Asia \/ Baring Private Equity Asia","highestDevelopmentStatusID":"15","companyTruncated":"Baring Private Equity Asia \/ Baring Private Equity Asia"}]

    Find Clinical Drug Pipeline Developments & Deals by Baring Private Equity Asia

    Menu

    Baring Private Equity Asia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Baring Private Equity Asia

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Baring Private Equity Asia

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Savolitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Hutchmed

                            Deal Size : $100.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Hutchmed Announces US$100 Million Equity Investment by Baring Private Equity Asia

                            Details : The agreement will aid in company's business growth as it looks to ramp up its oncology revenues from ELUNATE®, SULANDA® and the potential upcoming approval of savolitinib, likely to be a first-in-class selective c-MET inhibitor in China.

                            Product Name : Orpathys

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 08, 2021

                            Lead Product(s) : Savolitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Hutchmed

                            Deal Size : $100.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth